Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949366 | 0.83 | HTR3A (0.56) | KDM4EMAPTHTR7EGFR | |
| SCHEMBL3340549 | 0.80 | LTA4H (0.48) | ALDH1A1MAPTHTR7AHRNR4A2 | |
| SCHEMBL3719392 | 0.79 | HTR7 (0.47) | ALDH1A1MAPTPKMHTR7AHR | |
| SCHEMBL13797779 | 0.79 | HTR7 (0.42) | HTR7EGFRGABRPGABRDGABRA1 | |
| SCHEMBL1537900 | 0.78 | HTR3E (0.57) | HTR7CYP3A4AHRNR4A2CYP2A6 | |
| SCHEMBL4309899 | 0.77 | HTR7 (0.53) | KDM4EHTR7LTA4H | |
| SCHEMBL442575 | 0.76 | JAK2 (0.56) | KDM4EALDH1A1MAPTHTR7 | |
| SCHEMBL31141983 | 0.76 | LGMN (0.47) | ALDH1A1MAPTHTR7EGFRGABRP | |
| SCHEMBL30619464 | 0.76 | JAK2 (0.56) | KDM4EALDH1A1MAPTHTR7 | |
| SCHEMBL21336580 | 0.75 | HRH3 (0.64) | KDM4EALDH1A1MAPTPKMHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| CN-101298433-A | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy | BIOVITRUM AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-100378074-C | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | KDM4E 1137/4885ALDH1A1 763/4885MAPT 2795/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | KDM4E 1472/4885ALDH1A1 1009/4885MAPT 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.